Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics director-affiliated entities reported open-market sales of 105,565 shares of common stock. The transactions occurred on June 4, 5 and 8, 2026 at weighted average prices around $0.40 per share, within disclosed price ranges from $0.3706 to $0.454.
The sales were made by investment entities associated with Luke Evnin and were effected under a pre-established Rule 10b5-1 trading plan dated March 26, 2026. After these transactions, those entities collectively held 377,211 shares of Werewolf Therapeutics common stock, with Evnin disclaiming beneficial ownership beyond his pecuniary interest.
Werewolf Therapeutics director-affiliated funds reported open-market sales of 139,803 shares of Common Stock over three days. Entities associated with Luke Evnin sold 80,459 shares on June 1 at a weighted average price of $0.47, 29,595 shares on June 2 at $0.45, and 29,749 shares on June 3 at $0.42 per share.
The transactions were executed pursuant to a Rule 10b5-1 trading plan dated March 26, 2026, and are reported as indirect ownership. After the June 3 transactions, the affiliated entities collectively held 482,776 shares, and Evnin disclaims beneficial ownership except to the extent of his pecuniary interest.
Entities affiliated with Werewolf Therapeutics director Luke Evnin sold 141,106 shares of common stock in open-market transactions. The sales occurred over three days at weighted average prices of about $0.48, $0.46 and $0.45 per share, with individual trades ranging between $0.44 and $0.49705.
The trades were executed under a pre-established Rule 10b5‑1 trading plan dated March 26, 2026. After these transactions, entities associated with Evnin indirectly hold 622,579 shares of Werewolf Therapeutics common stock, spread across several MPM investment vehicles.
Werewolf Therapeutics director-related entities reported open-market sales of common stock. Investment entities associated with Luke Evnin sold a total of 191,762 shares of Werewolf Therapeutics, Inc. common stock in three open-market transactions on May 21, May 22 and May 26, 2026, at reported prices of $0.42, $0.45 and $0.47 per share, respectively. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 26, 2026. After these sales, the entities collectively held 763,685 shares indirectly, spread across several MPM-managed funds and LLCs.